Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | F2 | P00734 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630620 | 0.99 | OPRD1 (0.38) | OPRD1OPRM1OPRK1F2MEN1 | |
| SCHEMBL29590467 | 0.90 | GRPR (0.39) | OPRD1OPRM1OPRK1F2 | |
| SCHEMBL32677418 | 0.89 | SLC15A2 (0.43) | F2 | |
| SCHEMBL29373629 | 0.89 | ECE1 (0.39) | MEN1KMT2AECE1BACE1 | |
| SCHEMBL30192164 | 0.88 | BACE1 (0.36) | ECE1BACE1 | |
| SCHEMBL30504749 | 0.87 | OPRM1 (0.36) | OPRD1OPRM1OPRK1F2 | |
| SCHEMBL31590090 | 0.87 | OPRD1 (0.35) | OPRD1OPRM1OPRK1F2MEN1 | |
| SCHEMBL11028917 | 0.86 | OPRD1 (0.37) | OPRD1OPRM1OPRK1 | |
| SCHEMBL11028909 | 0.86 | OPRD1 (0.37) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29592282 | 0.86 | OPRD1 (0.42) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | OPRD1 4566/4885OPRM1 4101/4885OPRK1 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.